SAB Biotherapeutics is a clinical-stage biopharma developing a proprietary platform to rapidly produce fully human polyclonal antibody immunotherapies at commercial scale without human plasma donors. Its lead candidate, SAB-185, is an anti‑SARS‑CoV‑2 fully human polyclonal antibody therapeutic poised to begin clinical trials. The company’s platform is being applied across infectious disease, autoimmune, inflammation and oncology programs. SAB has secured program-specific funding from BARDA (up to $9.4M) and operates under a $27M Rapid Response contract with the DoD JPEO‑CBRND. With the newly closed Series B, SAB reports approximately $50M in equity raised and more than $100M in non-dilutive grants and contracts since founding. The company is working with partners to accelerate delivery of its immunotherapy platform in response to COVID‑19 and other indications. SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing fully human immunotherapies using its DiversitAb™ platform to produce fully human immunoglobulins outside of humans. The platform is described as scalable and dynamic, enabling large-scale production with shorter development cycles than current methods. SAB is focused on targets across cancer, autoimmune diseases and infectious diseases, including influenza and Type 1 diabetes. The company plans to use the new capital to accelerate growth, expand operations and advance its immunotherapy platform toward commercial targets. SAB is progressing clinical development and intends to proceed to Phase 2 clinical trials. Since 2014 the company has developed immunotherapies against more than a dozen targets, achieved 100% efficacy in pre-clinical testing and completed successful Phase 1 clinical trials. It has also secured substantial grants, contracts and in-kind services from BARDA and the NIH. SAB Biotherapeutics develops antibody therapeutics using its DiversitAb™ Platform, which leverages transchromosomic cattle (Tc Bovine™) engineered to produce fully human immunoglobulin G antibodies. The company is clinical-stage and focuses on both the science and large-scale manufacturing of antibody products. Its platform is being applied to infectious diseases, including influenza, with potential relevance to public health threats, rare conditions, and long-term diseases. SAB partnered with the University of South Dakota Sanford School of Medicine on the influenza program and engaged through the BioSNTR distributed research initiative. The company is led by President and CEO Eddie Sullivan, Ph.D. Financially, the company received a Small Business Innovation Research award to support production and preclinical testing of its influenza antibody candidate.

Total raised

$37M

Funding rounds

3

Latest round

Series B

Latest activity

Jul 2020